Gilead Sciences (GILD) Tops Q2 EPS by 5c, Beats on Revenue; Offers FY25 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Gilead Sciences Announces Second Quarter 2025 Financial Results
August 7, 2025 4:22 PM EDTProduct Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion
Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations.
This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the worlds first twice-yearly HIV prevention option, said Daniel ODay, Gileads Chairman and Chief Executive Officer. Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the... More
